RevealDx Announces Distribution Agreement and Investment from 4DMedical 4DMedical to Distribute RevealAI-Lung in the US, Europe, Australia and New Zealand Seattle, WA – August 3, 2026 – RevealDx, a leader in AI characterization of lung nodules, announced today, following World Lung Cancer Day, a distribution agreement and strategic investment of $3.4 million by 4DMedical (ASX: … RevealDx Announces Distribution Agreement and Investment from 4DMedical
News
Nashville, TN and Seattle, WA – May 14, 2026 – Azra AI, the leading end-to-end enterprise platform for incidental findings and oncology workflow automation, and RevealDx, the leader in AI tools for the characterization of lung nodules, today announced a new partnership. This partnership builds upon Azra AI’s recent acquisition of Thynk health, which provides … Azra and RevealDx Announce Partnership
Seattle, WA – February 3, 2026 – RevealDx, a leader in AI tools for the characterization of lung nodules, announced FDA clearance of RevealAI-Lung. The company had previously announced MDR Certification in November of 2025. The RevealDx technology characterizes incidental lung nodules by producing a Malignancy Similarity Index (mSI™), a score that is intended to … RevealDx Receives FDA Clearance for AI Powered Lung Nodule Risk Assessment
RDX clinical radiology pub
RevealDx MDR Announcement FINAL.docx